Thursday 8 October 2026
Night EditionRSS
ZOTPAPER

News without the noise

ZOTPAPER
AI

Google DeepMind and Meta invest $300 million in Zuckerberg-backed Biohub virtual cell project

The investment is part of a $1.8 billion initiative to build AI-powered biological datasets for disease research.

By LineZotpaper
Published
Read Time2 min
Google DeepMind, Meta, and AI drug discovery startup Isomorphic Labs are jointly investing $300 million into Biohub, the nonprofit biomedical research organization founded by Mark Zuckerberg and Priscilla Chan. The funding is part of a larger $1.8 billion initiative to create a virtual cell, a digital model that could allow researchers to simulate biological processes and accelerate disease prevention and treatment.

The investment was announced as part of a broader push to build AI datasets that could help researchers "ask, predict, and answer biological questions digitally," according to Biohub. The goal is to create a "virtual cell" that scientists can use to run simulations, test hypotheses, and discover new ways to prevent and manage diseases.

Biohub was founded in 2016 by Mark Zuckerberg and Priscilla Chan through the Chan Zuckerberg Initiative. The organization has long aimed to combat diseases by developing advanced AI tools for biomedical research. The new funding brings together three major players in artificial intelligence: Google DeepMind, which has made breakthroughs in protein structure prediction with AlphaFold; Meta, which has invested heavily in AI research; and Isomorphic Labs, a DeepMind spinout focused on AI-driven drug discovery.

The US Department of Energy is also involved in the initiative, which will support the creation of large-scale biological datasets needed to train AI models. The virtual cell effort is expected to provide researchers with a platform to simulate cellular behavior, potentially reducing the need for physical experiments and speeding up the development of treatments.

The $1.8 billion initiative includes the $300 million from the three companies, with additional funding from other partners and government sources. Biohub has not yet detailed the exact timeline for the virtual cell project, but the investment signals a significant commitment to applying AI to biology.

§

Analysis

Why This Matters

  • The virtual cell could transform drug discovery and disease research by allowing scientists to run millions of digital experiments instead of time-consuming lab work.
  • The collaboration between Google DeepMind, Meta, and Isomorphic Labs shows the growing convergence of big tech, AI, and biomedical research.
  • If successful, the project could reduce the cost and time required to develop new treatments for major diseases.

Background

Biohub is a nonprofit biomedical research organization launched by Mark Zuckerberg and Priscilla Chan as part of the Chan Zuckerberg Initiative. It has focused on applying AI and advanced computing to biology, with an earlier effort involving the use of GPUs for medical research. The latest project aims to build a comprehensive digital model of a human cell, a goal that requires massive datasets and cutting-edge AI models.

Key Perspectives

[Biohub and the Chan Zuckerberg Initiative]: They view the virtual cell as a tool to democratize biological research, enabling any scientist to run simulations and ask questions that would otherwise require expensive experiments. [Google DeepMind and Isomorphic Labs]: These organizations bring expertise in AI-driven protein folding and drug discovery. For them, the partnership is a way to apply their models to real-world biological questions at scale. [Meta]: Meta's involvement signals an interest in applying its AI research infrastructure to scientific problems, beyond its core social media and advertising business.

What to Watch

  • Whether the virtual cell project produces publicly available datasets that accelerate broader AI-for-science research.
  • The timeline and milestones Biohub sets for demonstrating a working prototype of the virtual cell.
  • Potential ethical and regulatory discussions around using AI models to simulate human biology and guide treatment decisions.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workReport an errorSubscribe